Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-04-2006

A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation

Auteurs: Jessica A. Hellings, Jennifer R. Zarcone, R. Matthew Reese, Maria G. Valdovinos, Janet G. Marquis, Kandace K. Fleming, Stephen R. Schroeder

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 3/2006

Abstract

Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies. This longer-duration study includes a broad sample. Forty subjects, aged 8–56 years (mean=22), all with mental retardation and 36 with autism spectrum disorders participated in this 22-week crossover study, with 24 weeks of open maintenance thereafter. Of 40 subjects, 23 (57.5%) responded fully (50% decrease in Aberrant Behavior Checklist-Community Irritability subscale score), while 35 subjects (87.5%) showed a 25% decrease. Gender, mood disorder, and antiseizure medications did not alter response. Increased appetite and weight gain were common. Low dose risperidone was effective for aggressive behavior in persons with MR. More long-term studies are needed, incorporating weight control interventions.

vorige artikel Normal Physiological Emotions but Differences in Expression of Conscious Feelings in Children with High-Functioning Autism

volgende artikel The Gluten-Free, Casein-Free Diet In Autism: Results of A Preliminary Double Blind Clinical Trial

Aman M. G., Singh N. N., Stewart A. W., Field C. J., (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects American Journal of Mental Deficiency 89: 485–491PubMed

Aman M. G., De Smedt G., Derivan A., Lyons B., Findling R. L., (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behavior disorders in children with subaverage intelligence American Journal Psychiatry 159: 1337–1346CrossRef

American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4 Washington, DC: American Psychiatric Association

Anderson L. T., Campbell M., Adams P., Small A. M., Perry R., Shell J., (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic childrenJournal of Autism and Developmental Disorders, 19: 227–239CrossRefPubMed

Anderson L. T., Campbell M., Grega D. M., Perry R., Small A. M., Green W. H., (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptomsAmerican Journal of Psychiatry 41: 1195–1202

Breese G. R. (2002). Age-dependent reduction of brain dopamine: Relationship to self-injurious behavior. In: Schroeder S. R., Oster-Granite M. L., Thompson T. (Eds.), Self-injurious behavior: Gene–brain-behavior relationships, Washington, DC: American Psychological Association (pp. 279–287)CrossRef

Campbell M., Armenteros J. L., Malone R. P., Adams P. B., Eisenberg Z. W., Overall J. E., (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study Journal of the American Academy of Child and Adolescent Psychiatry 36: 835–843CrossRefPubMed

Cook E. H., Leventhal B. L., (1996). The serotonin system in autism Current Opinions in Pediatrics 8: 348–354CrossRef

Cook E. H. Jr., Courchesne R., Lord C., Cox N. J., Yan S., Lincoln A., (1997). Evidence of linkage between the serotonin transporter and autistic disorder Molecular Psychiatry 2: 247–250CrossRefPubMed

Gordon C. T., State R. C., Nelson J. E., Hamburger S., Rapoport J. L., (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorderArchives of General Psychiatry, 50: 441–447PubMed

Gualtieri, C. T. (1984). The Neuroleptic Side Effects Checklist. Unpublished Scale available from the author

Guy W., (1976). Assessment manual for psychopharmacology. Washington, DC: U.S. Government Printing Office

Hellings J. A., Zarcone J. R., Crandall K., Wallace D., Schroeder S. R., (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autismJournal of Child and Adolescent Psychopharmacology 11: 229–238CrossRefPubMed

Helligs, J. A., Zarcone, J. R., Valdovinos, M. G., Reese, R. M., Gaughan, E., Schroeder, S. R. (2005). Risperidone-induced prolactin elevation in a study of children, adolescents and adults with mental retardation and pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 15: 885–892CrossRefPubMed

Kawachi, I. (1999). Health consequences of weight gain. In: Therapeutic advances in psychoses: Weight gain associated with use of psychotropic drugs. Belle Mead, NJ: Excerpta Medica, Inc 1–3

Kim S. J., Cox N., Courcheshe R., Lord C., Corsello C., Ashoomoff N. et al. (2002). Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder Molecular Psychiatry 7: 278–288CrossRefPubMed

Leiter R. G., (1948). Leiter international performance scale. Chicago, IL: Stoelting Co

McDougle C. J., Holmes J. P., Carlson D. C., Pelton G. H., Cohen D. J., Price L. H., (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders Archives of General Psychiatry 55: 633–641CrossRefPubMed

McDougle C. J., Naylor S. T., Cohen D. J., Volkmar F. R., Heninger G. R., Price L., (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder Archives of General Psychiatry 53: 1001–1008PubMed

Meltzer H. Y., (1995). The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics Journal of Clinical Psychopharmacol, 15: 2S–3S

Research Units on Pediatric Psychopharmacology Autism Network (2002). Risperidone in children with autism and serious behavioral problemsNew England Journal of Medicine347: 314–321CrossRef

Schroeder S. R., Rojahn J., Reese R. M., (1997). Brief report: Reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardationJournal of Autism and Developmental Disorders 27: 89–102CrossRefPubMed

Siegel S., Castellan N. J. Jr., (1988). Nonparametric statistics for the behavioral sciences, 2. New York: McGraw-Hill

Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., Carroll, A., & The Risperidone Conduct Study Group (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQ’s. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1026–1036

Sprague R. L., Kalachnik J. E., Shaw K. M., (1989). Psychometric properties of the dyskinesia identification system: Condensed user scale (DISCUS) Mental Retardation, 27: 141–148PubMed

Vitiello, B. (2002). Assessment of adverse events and preservation of blindness in clinical trials. Oral presentation at the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU). Boca Raton, FL

Wechsler D., (1981). Manual for the Welchsler adult intelligence scale-revised. San Antonio, Tex: Psychological Corp

Wechsler D., (1991). Manual for the Wechsler intelligence scale for children, 3. San Antonio, TX: Psychological Corp

Zarcone J. R., Hellings J. A., Crandall K., Reese R. M., Marquis J., Fleming K. et al. (2001). Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures.American Journal of Mental Retardation 106: 525–538CrossRefPubMed

Titel: A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation
Auteurs: Jessica A. Hellings
Jennifer R. Zarcone
R. Matthew Reese
Maria G. Valdovinos
Janet G. Marquis
Kandace K. Fleming
Stephen R. Schroeder
Publicatiedatum: 01-04-2006
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 3/2006
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-006-0078-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 3/2006

Cognitive and Symptom Profiles in High-Functioning Pervasive Developmental Disorder Not Otherwise Specified and Attention-Deficit/Hyperactivity Disorder

Brief Report: “The Autism Epidemic”. The Registered Prevalence of Autism in a Swedish Urban Area

Normal Physiological Emotions but Differences in Expression of Conscious Feelings in Children with High-Functioning Autism

The Autism-Spectrum Quotient (AQ)—Adolescent Version

TEACCH Conference Autism in Adolescents and Adults May 18–19, 2006

Familial Autoimmune Thyroid Disease as a Risk Factor for Regression in Children with Autism Spectrum Disorder: A CPEA Study